For the second consecutive year, Valbiotis is participating in this scientific event co-organized by the Quebec Society of lipidology, nutrition and metabolism (SQLNM) and the Cardiometabolic Health, Diabetes and Obesity (CMDO) research network. This symposium, which also brings together experts from the National Institute for Functional Foods (INAF), a partner of Valbiotis, covers topics related to cardiometabolic disorders, especially dyslipidemia. It takes place from 8 to 10 February 2023 in Magog, Canada. Valbiotis will present the positive results of the Phase II HEART clinical study with TOTUM•070 for hypercholesterolemia, as well as in vitro mode of action work. The Phase II HEART study demonstrated in 2022 the efficacy of the innovative active substance TOTUM•070 on blood levels of LDL cholesterol and triglycerides. The R&D teams at Valbiotis will be pleased to discuss these promising data with the experts from Quebec.
See poster 